Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).
Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Ginos B, Heying E, Wu TT, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP, Alberts SR. Yoon HH, et al. Among authors: wigle da. Eur J Cancer. 2021 Jun;150:214-223. doi: 10.1016/j.ejca.2021.03.025. Epub 2021 Apr 29. Eur J Cancer. 2021. PMID: 33934058 Free PMC article. Clinical Trial.
Overall survival and self-reported fatigue in patients with esophageal cancer.
Stauder MC, Romero Y, Kabat B, Atherton PJ, Geno D, Deschamps C, Jatoi A, Sloan JA, Botros M, Jung KW, Arora AS, Miller RC; EABE Registry Consortium. Stauder MC, et al. Support Care Cancer. 2013 Feb;21(2):511-9. doi: 10.1007/s00520-012-1537-1. Epub 2012 Jul 29. Support Care Cancer. 2013. PMID: 22842921
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.
Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, Hong TS, Leichman LP, Rajdev L, Resnick M, Kachnic LA, Seaward S, Mamon H, Diaz Pardo DA, Anderson CM, Shen X, Sharma AK, Katz AW, Salo J, Leonard KL, Moughan J, Crane CH. Safran HP, et al. Among authors: wigle d. Lancet Oncol. 2022 Feb;23(2):259-269. doi: 10.1016/S1470-2045(21)00718-X. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038433 Free PMC article. Clinical Trial.
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, Fruth BF, Beamer SE, Kim Y, Harrington SM, Pitot HC, Sanhueza CT, Feng Y, Herrmann J, McWilliams RR, Lucien F, Huang BQ, Ma WW, Bekaii-Saab TS, Dong H, Wigle D, Ahn DH, Hallemeier CL, Blackmon S, Yoon HH. Zhu M, et al. Clin Cancer Res. 2022 Jul 15;28(14):3021-3031. doi: 10.1158/1078-0432.CCR-22-0413. Clin Cancer Res. 2022. PMID: 35552651 Free PMC article. Clinical Trial.
Survival After Surgical Resection of Stage IV Esophageal Cancer.
Saddoughi SA, Reinersman JM, Zhukov YO, Taswell J, Mara K, Harmsen SW, Blackmon SH, Cassivi SD, Nichols F 3rd, Shen KR, Wigle DA, Allen MS. Saddoughi SA, et al. Among authors: wigle da. Ann Thorac Surg. 2017 Jan;103(1):261-266. doi: 10.1016/j.athoracsur.2016.06.070. Epub 2016 Sep 9. Ann Thorac Surg. 2017. PMID: 27623270
FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.
Arnett AL, Packard AT, Mara K, Mansfield AS, Wigle DA, Haddock MG, Park SS, Olivier KR, Garces YI, Merrell KW. Arnett AL, et al. Among authors: wigle da. Pract Radiat Oncol. 2017 Nov-Dec;7(6):e531-e541. doi: 10.1016/j.prro.2017.04.013. Epub 2017 Apr 19. Pract Radiat Oncol. 2017. PMID: 28733185 Clinical Trial.
232 results